Trials / Completed
CompletedNCT00918281
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET acquisitions, and tumors demonstrate detectable levels of 18F uptake on PET.
Conditions
- Solid Tumors
- High Grade Gliomas
- Lung Cancer
- Head and Neck Cancer
- Sarcoma
- Renal Cell Carcinoma
- Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluciclatide Injection | Fluciclatide Injection (AH111585 (18F) Injection) |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2011-09-01
- Completion
- 2011-10-01
- First posted
- 2009-06-11
- Last updated
- 2014-06-09
- Results posted
- 2014-06-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00918281. Inclusion in this directory is not an endorsement.